Page 9 - Merck Sharp News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ATD announces several new board members.

Results Reveal Mechanism of Action and Correlative Analyses DataHELSINKI, Finland, April 10, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies presented promising preliminary safety and efficacy data from their ongoing Phase I clinical trial (NCT05271318) in platinum resistant or refractory ovarian cancer patients at the American Association for Cancer Research (AACR) Annual Meeting 2024. TILT-123 in combination with MS

As per Future Market...

Objective To investigate whether use of glucagon-like peptide 1 (GLP1) receptor agonists is associated with increased risk of thyroid cancer. Design Scandinavian cohort study. Setting Denmark, Norway, and Sweden, 2007-21. Participants Patients who started GLP1 receptor agonist treatment were compared with patients who started dipeptidyl peptidase 4 (DPP4) inhibitor treatment, and in an additional analysis, patients who started sodium-glucose cotransporter 2 (SGLT2) inhibitor treatment. Main outcome measures Thyroid cancer identified from nationwide cancer registers. An active-comparator new us...

Beam Therapeutics (NASDAQ:BEAM – Get Free Report) and Gilead Sciences (NASDAQ:GILD – Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, profitability and analyst recommendations. Analyst Recommendations This is a breakdown of current […]